Pfizer Common Stock Net 2010-2024 | PFE
Pfizer common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
- Pfizer common stock net for the quarter ending September 30, 2024 was $0.480B, a 0.42% increase year-over-year.
- Pfizer common stock net for 2023 was $0.478B, a 0.42% increase from 2022.
- Pfizer common stock net for 2022 was $0.476B, a 0.63% increase from 2021.
- Pfizer common stock net for 2021 was $0.473B, a 0.64% increase from 2020.
Pfizer Annual Common Stock Net
(Millions of US $) |
| 2023 |
$478 |
| 2022 |
$476 |
| 2021 |
$473 |
| 2020 |
$470 |
| 2019 |
$468 |
| 2018 |
$467 |
| 2017 |
$464 |
| 2016 |
$461 |
| 2015 |
$459 |
| 2014 |
$455 |
| 2013 |
$453 |
| 2012 |
$448 |
| 2011 |
$445 |
| 2010 |
$444 |
| 2009 |
$443 |
Pfizer Quarterly Common Stock Net
(Millions of US $) |
| 2024-09-30 |
$480 |
| 2024-06-30 |
$480 |
| 2024-03-31 |
$480 |
| 2023-12-31 |
$478 |
| 2023-09-30 |
$478 |
| 2023-06-30 |
$478 |
| 2023-03-31 |
$478 |
| 2022-12-31 |
$476 |
| 2022-09-30 |
$476 |
| 2022-06-30 |
$476 |
| 2022-03-31 |
$476 |
| 2021-12-31 |
$473 |
| 2021-09-30 |
$473 |
| 2021-06-30 |
$472 |
| 2021-03-31 |
$472 |
| 2020-12-31 |
$470 |
| 2020-09-30 |
$470 |
| 2020-06-30 |
$470 |
| 2020-03-31 |
$470 |
| 2019-12-31 |
$468 |
| 2019-09-30 |
$468 |
| 2019-06-30 |
$468 |
| 2019-03-31 |
$468 |
| 2018-12-31 |
$467 |
| 2018-09-30 |
$466 |
| 2018-06-30 |
$465 |
| 2018-03-31 |
$465 |
| 2017-12-31 |
$464 |
| 2017-09-30 |
$463 |
| 2017-06-30 |
$463 |
| 2017-03-31 |
$463 |
| 2016-12-31 |
$461 |
| 2016-09-30 |
$461 |
| 2016-06-30 |
$461 |
| 2016-03-31 |
$460 |
| 2015-12-31 |
$459 |
| 2015-09-30 |
$459 |
| 2015-06-30 |
$458 |
| 2015-03-31 |
$458 |
| 2014-12-31 |
$455 |
| 2014-09-30 |
$455 |
| 2014-06-30 |
$454 |
| 2014-03-31 |
$454 |
| 2013-12-31 |
$453 |
| 2013-09-30 |
$452 |
| 2013-06-30 |
$451 |
| 2013-03-31 |
$450 |
| 2012-12-31 |
$448 |
| 2012-09-30 |
$447 |
| 2012-06-30 |
$447 |
| 2012-03-31 |
$446 |
| 2011-12-31 |
$445 |
| 2011-09-30 |
$445 |
| 2011-06-30 |
$445 |
| 2011-03-31 |
$444 |
| 2010-12-31 |
$444 |
| 2010-09-30 |
$443 |
| 2010-06-30 |
$443 |
| 2010-03-31 |
$443 |
| 2009-12-31 |
$443 |
| 2009-09-30 |
$443 |
| 2009-06-30 |
$443 |
| 2009-03-31 |
$443 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$142.241B |
$58.496B |
|
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
|
